Cytochrome P-450 CYP2C9

• 

  Subject Areas on Research

  • A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. 
  • A pharmacogenetic versus a clinical algorithm for warfarin dosing. 
  • CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. 
  • Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. 
  • Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. 
  • Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms. 
  • Estimation of the warfarin dose with clinical and pharmacogenetic data. 
  • Genetic-based dosing in orthopedic patients beginning warfarin therapy. 
  • Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. 
  • Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. 
  • Pharmacogenomics for personalized pain medicine. 
  • Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. 
  • Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. 
  • Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 
  • The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. 
  • The long and winding road to warfarin pharmacogenetic testing. 
  • The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 
  • Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. 
  • Use of pharmacogenetics to guide warfarin therapy. 
  • Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.